Search

Your search keyword '"Jong, Dirk J. de"' showing total 6 results
Start Over Author "Jong, Dirk J. de" Search Limiters Full Text
6 results on '"Jong, Dirk J. de"'

1. Tu1498: WITHDRAWAL OF THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS IN STABLE REMISSION: A PROSPECTIVE, MULTICENTER COHORT STUDY

Author

Savelkoul, Edo, primary, Mahmoud, Remi, additional, Jong, Dirk J. De, additional, Dop, Willemijn A. van, additional, Romkens, Tessa E.H, additional, Nissen, Loes H., additional, Mahmmod, Nofel, additional, Boeckel, Petra G. van, additional, Lutgens, Maurice, additional, Mares, Wout, additional, Epping, Ludger, additional, Minderhoud, Itta M., additional, Jansen, Jeroen M., additional, Gisbertz, Ingrid A., additional, Boekema, Paul, additional, Koning, Daan de, additional, Horje, Carmen S. Horjus Talabur, additional, Jharap, Bindia, additional, Oldenburg, Bas, additional, and Hoentjen, Frank, additional

Published
2022
Full Text
View/download PDF

2. Genetic deficiency of NOD2 confers resistance to invasive aspergillosis

Author

Gresnigt, Mark S., primary, Cunha, Cristina, additional, Jaeger, Martin, additional, Gonçalves, Samuel M., additional, Malireddi, R. K. Subbarao, additional, Ammerdorffer, Anne, additional, Lubbers, Rosalie, additional, Oosting, Marije, additional, Rasid, Orhan, additional, Jouvion, Grégory, additional, Fitting, Catherine, additional, Jong, Dirk J. de, additional, Lacerda, João F., additional, Campos, António, additional, Melchers, Willem J. G., additional, Lagrou, Katrien, additional, Maertens, Johan, additional, Kanneganti, Thirumala-Devi, additional, Carvalho, Agostinho, additional, Ibrahim-Granet, Oumaima, additional, and van de Veerdonk, Frank L., additional

Published
2018
Full Text
View/download PDF

3. Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease

Author

Spekhorst, Lieke M, primary, Oldenburg, Bas, additional, Bodegraven, Ad A van, additional, Jong, Dirk J de, additional, Imhann, Floris, additional, Jong, Andrea E van der Meulen-de, additional, Pierik, Marieke J, additional, Woude, Janneke C van der, additional, Dijkstra, Gerard, additional, D’Haens, Geert, additional, Löwenberg, Mark, additional, and Weersma, Rinse K, additional

Published
2017
Full Text
View/download PDF

4. Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease

Author

Spekhorst, Lieke M, primary, Imhann, Floris, additional, Festen, Eleonora AM, additional, Bodegraven, Ad A van, additional, Boer, Nanne KH de, additional, Bouma, Gerd, additional, Fidder, Herma H, additional, D’Haens, Geert, additional, Hoentjen, Frank, additional, Hommes, Daan W, additional, Jong, Dirk J de, additional, Löwenberg, Mark, additional, Maljaars, PW Jeroen, additional, Meulen-de Jong, Andrea E van der, additional, Oldenburg, Bas, additional, Pierik, Marieke J, additional, Ponsioen, Cyriel Y, additional, Stokkers, Pieter C, additional, Verspaget, Hein W, additional, Visschedijk, Marijn C, additional, van der Woude, C Janneke, additional, Dijkstra, Gerard, additional, and Weersma, Rinse K, additional

Published
2017
Full Text
View/download PDF

6. Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease.

Author

Nijmeijer, Rian M., Gadaleta, Raffaella M., van Mil, Saskia W. C., Bodegraven, Adriaan A. van, Crusius, J. Bart A., Dijkstra, Gerard, Hommes, Daan W., Jong, Dirk J. de, Stokkers, Pieter C. F., Verspaget, Hein W., Weersma, Rinse K., Woude, C. Janneke van der, Stapelbroek, Janneke M., Schipper, Marguerite E. I., Wijmenga, Cisca, Erpecum, Karel J. van, and Oldenburg, Bas

Subjects
FARNESOID X receptor, MESSENGER RNA, HUMAN genetic variation, INFLAMMATORY bowel diseases, LABORATORY mice, COLITIS, CROHN'S disease, ENTEROHEPATIC circulation, BILE salts
Abstract

Background: We previously showed that activation of the bile salt nuclear receptor Farnesoid X Receptor (FXR) protects against intestinal inflammation in mice. Reciprocally, these inflammatory mediators may decrease FXR activation. We investigated whether FXR activation is repressed in the ileum and colon of inflammatory bowel disease (IBD) patients in remission. Additionally, we evaluated whether genetic variation in FXR is associated with IBD. Methods: mRNA expression of FXR and FXR target gene SHP was determined in ileal and colonic biopsies of patients with Crohn's colitis (n = 15) and ulcerative colitis (UC; n = 12), all in clinical remission, and healthy controls (n = 17). Seven common tagging SNPs and two functional SNPs in FXR were genotyped in 2355 Dutch IBD patients (1162 Crohn's disease (CD) and 1193 UC) and in 853 healthy controls. Results: mRNA expression of SHP in the ileum is reduced in patients with Crohn's colitis but not in patients with UC compared to controls. mRNA expression of villus marker Villin was correlated with FXR and SHP in healthy controls, a correlation that was weaker in UC patients and absent in CD patients. None of the SNPs was associated with IBD, UC or CD, nor with clinical subgroups of CD. Conclusions: FXR activation in the ileum is decreased in patients with Crohn's colitis. This may be secondary to altered enterohepatic circulation of bile salts or transrepression by inflammatory signals but does not seem to be caused by the studied SNPs in FXR. Increasing FXR activity by synthetic FXR agonists may have benefit in CD patients. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results